VAT-1 is a novel pathogenic factor of progressive benign prostatic hyperplasia

Area of Science:

• Urology
• Cell Biology
• Molecular Medicine

Background:

• Benign prostatic hyperplasia (BPH) causes lower urinary tract symptoms (LUTS) due to prostatic stromal hyperplasia (STH).
• The underlying mechanisms of STH are not fully understood.
• A novel, clinically relevant STH experimental model was previously established.

Purpose of the Study:

• To elucidate the mechanism of prostatic STH.
• To identify key factors involved in BPH pathogenesis.
• To evaluate a novel therapeutic compound in an experimental BPH model.

Main Methods:

• Affinity pull-down and mass spectrometry to identify compound-binding proteins.
• RNA interference (RNAi) to assess the role of the binding protein in cell proliferation.
• Immunohistochemistry to evaluate protein expression in BPH tissues and models.

Main Results:

• A benzimidazole derivative (Benz) suppressed urogenital sinus (UGS) growth and prostate stromal cell (PrSC) proliferation.
• Vesicle amine transport protein-1 (VAT-1) was identified as the specific binding protein for Benz.
• VAT-1 expression was elevated in BPH tissues; VAT-1 inhibition reduced PrSC and UGS growth.

Conclusions:

• VAT-1 is a novel pathogenic factor contributing to BPH development.
• VAT-1 plays a crucial role in prostate stromal cell proliferation.
• Targeting VAT-1 presents a potential therapeutic strategy for BPH.